利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.027 秒)

    Thermostable phytase variants
    13.
    发明授权
    Thermostable phytase variants 有权
    热稳定的植酸酶变体

    公开(公告)号：US09173421B2

    公开(公告)日：2015-11-03

    申请号：US13636008

    申请日：2011-03-25

    申请人： Leonardo De Maria ,  Lars Kobberoee Skov ,  Michael Skjoet

    发明人： Leonardo De Maria ,  Lars Kobberoee Skov ,  Michael Skjoet

    IPC分类号： C12N9/16 ,  C12N15/00 ,  C12P7/00 ,  A23K1/18 ,  A23K1/00 ,  A23K1/165 ,  C12P7/06

    CPC分类号： C12P7/06 ,  A23K10/10 ,  A23K10/14 ,  A23K50/75 ,  C12N9/16 ,  C12Y301/03008 ,  Y02E50/17

    摘要： The present invention relates to a method for producing phytase variants has at least 70% identity to a phytase derived from Buttiauxella and comprises at least one additional disulfide bond as compared to this phytase. These phytase variants have modified, preferably improved, properties, such as thermostability, temperature profile, pH profile, specific activity, performance in animal feed, reduced protease sensitiliby, and/or an modified glycosylation pattern. The invention also relates to the variants produced, DNA encoding these phytases, methods of their production, as well as the use thereof, e.g. in animal feed and animal feed additives.

    摘要翻译： 本发明涉及一种生产植酸酶变体的方法与来自Buttiauxella的植酸酶具有至少70％的同一性，并且与该植酸酶相比包含至少一个另外的二硫键。 这些植酸酶变体具有修饰的，优选改进的性质，例如热稳定性，温度曲线，pH曲线，比活性，动物饲料中的性能，降低的蛋白酶敏感性和/或修饰的糖基化模式。 本发明还涉及所生产的变体，编码这些植酸酶的DNA，其生产方法及其用途，例如， 在动物饲料和动物饲料添加剂中。

    Lipase variants for pharmaceutical use
    14.
    发明授权
    Lipase variants for pharmaceutical use 有权
    用于药物用途的脂肪酶变体

    公开(公告)号：US09029115B2

    公开(公告)日：2015-05-12

    申请号：US13587043

    申请日：2012-08-16

    申请人： Allan Svendsen ,  Michael Skjoet ,  Deborah Yaver ,  Lars Lehmann Hylling Christensen ,  Signe Eskildsen Larsen ,  Nina Lundin ,  Michael Lamsa ,  Peter Colin Gregory

    发明人： Allan Svendsen ,  Michael Skjoet ,  Deborah Yaver ,  Lars Lehmann Hylling Christensen ,  Signe Eskildsen Larsen ,  Nina Lundin ,  Michael Lamsa ,  Peter Colin Gregory

    IPC分类号： C12N9/20 ,  C12N9/14 ,  C12N9/26 ,  C12N9/48 ,  C12Q1/34 ,  C12Q1/40

    CPC分类号： A61K38/465 ,  A61K38/47 ,  A61K38/48 ,  C12N9/20

    摘要： The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.

    摘要翻译： 与包含SEQ ID NO：2的氨基酸1-269的Thermomyces lanuginosus（Humicola lanuginosa）脂肪酶相关的脂肪酶的药物用途，任选地与蛋白酶和/或淀粉酶组合。 医学适应症的例子有：消化系统疾病，胰腺外分泌功能不全（PEI），胰腺炎，囊性纤维化，I型糖尿病和/或II型糖尿病的治疗。 本发明的脂肪酶例如在体外具有改善的消化性能，在中性范围内的pH值改善的活性，在低pH下的改进的稳定性，并且对蛋白酶降解是稳定的，和/或在存在下是稳定的 的胃蛋白酶和胆汁盐。 本发明还涉及确定脂肪酶的体外消化性能的方法以及T.lanuginosus的脂肪酶的某些新颖变体。

    Lipase Variants for Pharmaceutical Use
    16.
    发明申请
    Lipase Variants for Pharmaceutical Use 审中-公开
    药用脂肪酶变体

    公开(公告)号：US20120308543A1

    公开(公告)日：2012-12-06

    申请号：US13587043

    申请日：2012-08-16

    申请人： Allan Svendsen ,  Michael Skjoet ,  Deborah Yaver ,  Lars Lehmann Hylling Christensen ,  Signe Eskildsen Larsen ,  Nina Lundin ,  Michael Lamsa ,  Peter Colin Gregory

    发明人： Allan Svendsen ,  Michael Skjoet ,  Deborah Yaver ,  Lars Lehmann Hylling Christensen ,  Signe Eskildsen Larsen ,  Nina Lundin ,  Michael Lamsa ,  Peter Colin Gregory

    IPC分类号： A61K38/54 ,  A61P3/00 ,  A61P3/10 ,  C12N9/20 ,  A61P1/00

    CPC分类号： A61K38/465 ,  A61K38/47 ,  A61K38/48 ,  C12N9/20

    摘要： The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.

    摘要翻译： 与包含SEQ ID NO：2的氨基酸1-269的Thermomyces lanuginosus（Humicola lanuginosa）脂肪酶相关的脂肪酶的药物用途，任选地与蛋白酶和/或淀粉酶组合。 医学适应症的例子有：消化系统疾病，胰腺外分泌功能不全（PEI），胰腺炎，囊性纤维化，I型糖尿病和/或II型糖尿病的治疗。 本发明的脂肪酶具有例如体外改进的消化性能，在中性范围内的pH值改善的活性，在低pH下的改进的稳定性，对蛋白酶降解是稳定的，和/或在存在时是稳定的 的胃蛋白酶和胆汁盐。 本发明还涉及确定脂肪酶的体外消化性能的方法以及T.lanuginosus的脂肪酶的某些新颖变体。